PositiveID Corporation to Debut Its iglucose Mobile Health Diabetes Management Solution at CTIA Wireless 2011
iglucose to be Featured at CTIA by Two Leaders in M2M Technology
iglucose Website Now Live at www.iglucose.com
DELRAY BEACH, Fla., March 21, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it will debut its iglucose™ mobile health diabetes management solution at CTIA Wireless 2011 in Orlando, March 22-24. The iglucose device connects to compatible data-capable glucometers to automatically communicate blood glucose readings to a secure online database and designated third parties at pre-determined intervals, such as healthcare professionals, caregivers and insurance providers. The product will be demonstrated live at Sierra Wireless' booth #1670 and
Connected Development's booth #1875, and the iglucose website is now accessible at www.iglucose.com.
PositiveID's iglucose system is a wireless communication solution that facilitates real-time diabetes management by automatically creating logs and journals, which the American Diabetes Association says are an important assessment of an individual's response to their diabetes care plan. iglucose provides next generation, real-time data to improve diabetes management by helping ensure patient compliance and data accuracy, and aiding in insurance reimbursement. This product has not been cleared for sale by the United States Food and Drug Administration.
Scott R. Silverman, Chairman and CEO of PositiveID, said, "We are very excited to unveil iglucose, an innovative healthcare solution that addresses a critical need - diabetes self-management. For the last year, we have worked diligently to bring the iglucose system to fruition, and we are honored that two leaders in the M2M field, Sierra Wireless and Connected Development, have chosen to showcase iglucose at their booths at CTIA Wireless."
The International CTIA WIRELESS® show is the premier wireless event representing a $1 trillion global marketplace that brings together wireless and converged communications, wireless broadband and mobile web.
According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that PositiveID's iglucose system will facilitate real-time diabetes management by automatically creating logs and journals; the ability of iglucose to improve diabetes management by helping ensure patient compliance and data accuracy, and aiding in insurance reimbursement; the likelihood that the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and
as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to receive clearance from the FDA to sell its product, the ability to successfully commercialize its iglucose system, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, August 13,
2010, and November 12, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Allison Tomek
Source: PositiveID Corporation
News Provided by Acquire Media
Close window | Back to top